Singapore Infectious Disease Drugs Market Analysis Report 2022 to 2030

Singapore Infectious Disease Drugs Market Analysis

$ 3999

Singapore Infectious Disease Drugs Market valued at $0.14 Bn in 2023, projected to reach $0.20 Bn by 2030 with a 4.87% CAGR. The market is growing due to the rising prevalence of infectious diseases, the emphasis on research and development, and the adoption of antiviral therapies. The market is dominated by key players like Temasek Life Sciences Laboratory, Acumen Research Laboratories, AbbVie Inc., Gilead Sciences, Merck & Co., F. Hoffman-La Roche Ltd., GlaxoSmithKline plc, Boehringer Ingelheim International GmbH, Janssen Pharmaceuticals, and Novartis AG.

ID: IN10SGPH012 CATEGORY: Pharmaceuticals GEOGRAPHY: Singapore AUTHOR: Aneri Parekh

Buy Now

Singapore Infectious Disease Drugs Market Executive Summary

Singapore Infectious Disease Drugs Market valued at $0.14 Bn in 2023, projected to reach $0.20 Bn by 2030 with a 4.87% CAGR.

The research, development, manufacturing, and distribution of pharmaceuticals intended to prevent, treat, or manage infectious diseases are the main areas of focus for the Singapore Infectious Disease Drugs Market. This market covers a broad spectrum of treatment areas, including vaccines, antivirals, antifungals, and antibiotics, among others, that are intended to battle different infectious organisms like bacteria, viruses, fungi, and parasites.

Several factors are contributing to the consistent expansion of the Singapore Infectious Disease Drugs Market. These factors include the increasing prevalence of infectious diseases, breakthroughs in drug development, and rising healthcare expenditures. When it comes to protecting the health of the people, infectious diseases present substantial problems to public health, which is why the market is so important.

In 2023, the global market for pharmaceuticals treating infectious illnesses was estimated to be worth $118.75 Bn. This increase has been brought on by an increase in diagnoses as well as government-sponsored public education campaigns on the control and prevention of infectious diseases. A shifting market environment is indicated by the growing degree of generic competition. Long-term improvement requires removing financial barriers and increasing access to therapy, particularly in underdeveloped countries. More industrial research and development will result from this.

Temasek Life Sciences Laboratory (TLL) is a Singapore research center founded by Temasek Holdings. TLL is a major player in the infectious illness medications market in Singapore, which is projected to grow to a value of $211.71 Mn by 2030. TLL made a significant contribution to the market by creating and releasing several medications for infectious diseases, such as Tcelna, a first-in-class T-cell immunomodulator for the treatment of Dengue fever, and Encyfo, a broad-spectrum antiviral medication for the treatment of respiratory syncytial virus (RSV) and influenza. Additionally, TLL is actively engaged in the investigation and creation of novel medications for infectious diseases, and it has a pipeline of potential treatments for conditions like HIV, malaria, and the Zika virus.

Singapore infectious disease drugs market

Market Dynamics

Market Growth Drivers:

Growing Incidence of Infectious Diseases: Singapore has seen an increase in the number of instances of infectious diseases due to urbanization, globalization, and antibiotic resistance.

Emphasis on Research and Development: To counter new infectious dangers, pharmaceutical companies and research institutes are actively working to produce novel medications.

Adoption of Antiviral Therapies: As a result of the development of innovative antiviral medications, there is an increasing focus on efficient means of treating viral illnesses, including hepatitis, influenza, and HIV/ AIDS.

Market Restraints:

Antimicrobial Resistance: The emergence of antibiotic resistance is a serious problem that makes it necessary to create new treatment approaches and restricts the efficacy of already available medications.

Regulatory Obstacles: Long approval procedures and strict regulations can make it difficult to release new medications for infectious diseases on schedule.

Economic Impact: Through increased healthcare expenses, reduced productivity, and disruptions to trade and tourism, infectious disease epidemics can have a significant negative impact on the economy, impeding the growth of the market.

Healthcare Policies and Regulatory Landscape

The Health Sciences Authority (HSA) is the statutory board that is part of the Ministry of Health in Singapore. It is a multidisciplinary organization to safeguard and enhance public health and safety by applying knowledge in medicine, pharmacy, and science. The drug's quality, safety, and efficacy will all be assessed as part of the technical review of the application by the HSA. The screening procedure may take up to 180 working days. The HSA adheres to strict quality, safety, and efficacy standards in compliance with international standards (ICH). This could lead to rigorous and time-consuming criteria for pre-clinical and clinical trials, particularly for novel drugs.

Competitive Landscape

Key Players:

Temasek Life Sciences Laboratory
Acumen Research Laboratories
AbbVie Inc.
Gilead Sciences
Merck & Co.
F. Hoffman-La Roche Ltd.
GlaxoSmithKline plc
Boehringer Ingelheim International GmbH
Janssen Pharmaceuticals
Novartis AG

1. Executive Summary
1.1 Disease Overview
1.2 Global Scenario
1.3 Country Overview
1.4 Healthcare Scenario in Country
1.5 Patient Journey
1.6 Health Insurance Coverage in Country
1.7 Active Pharmaceutical Ingredient (API)
1.8 Recent Developments in the Country

2. Market Size and Forecasting
2.1 Epidemiology of Disease
2.2 Market Size (With Excel & Methodology)
2.3 Market Segmentation (Check all Segments in Segmentation Section)

3. Market Dynamics
3.1 Market Drivers
3.2 Market Restraints

4. Competitive Landscape
4.1 Major Market Share

4.2 Key Company Profile (Check all Companies in the Summary Section)

4.2.1 Company
4.2.1.1 Overview
4.2.1.2 Product Applications and Services
4.2.1.3 Recent Developments
4.2.1.4 Partnerships Ecosystem
4.2.1.5 Financials (Based on Availability)

5. Reimbursement Scenario
5.1 Reimbursement Regulation
5.2 Reimbursement Process for Diagnosis
5.3 Reimbursement Process for Treatment

6. Methodology and Scope

Infectious Disease Drug Market Segmentation

By Disease

HIV
Influenza
Hepatitis
Tuberculosis
Malaria
Other

By Treatment

Antibacterial
Antiviral
Antiparasitic
Other

Methodology for Database Creation

Our database offers a comprehensive list of healthcare centers, meticulously curated to provide detailed information on a wide range of specialties and services. It includes top-tier hospitals, clinics, and diagnostic facilities across 30 countries and 24 specialties, ensuring users can find the healthcare services they need.

Additionally, we provide a comprehensive list of Key Opinion Leaders (KOLs) based on your requirements. Our curated list captures various crucial aspects of the KOLs, offering more than just general information. Whether you're looking to boost brand awareness, drive engagement, or launch a new product, our extensive list of KOLs ensures you have the right experts by your side. Covering 30 countries and 36 specialties, our database guarantees access to the best KOLs in the healthcare industry, supporting strategic decisions and enhancing your initiatives.

How Do We Get It?

Our database is created and maintained through a combination of secondary and primary research methodologies.

1. Secondary Research

With many years of experience in the healthcare field, we have our own rich proprietary data from various past projects. This historical data serves as the foundation for our database. Our continuous process of gathering data involves:

Analyzing historical proprietary data collected from multiple projects.
Regularly updating our existing data sets with new findings and trends.
Ensuring data consistency and accuracy through rigorous validation processes.

With extensive experience in the field, we have developed a proprietary GenAI-based technology that is uniquely tailored to our organization. This advanced technology enables us to scan a wide array of relevant information sources across the internet. Our data-gathering process includes:

Searching through academic conferences, published research, citations, and social media platforms
Collecting and compiling diverse data to build a comprehensive and detailed database
Continuously updating our database with new information to ensure its relevance and accuracy

2. Primary Research

To complement and validate our secondary data, we engage in primary research through local tie-ups and partnerships. This process involves:

Collaborating with local healthcare providers, hospitals, and clinics to gather real-time data.
Conducting surveys, interviews, and field studies to collect fresh data directly from the source.
Continuously refreshing our database to ensure that the information remains current and reliable.
Validating secondary data through cross-referencing with primary data to ensure accuracy and relevance.

Combining Secondary and Primary Research

By integrating both secondary and primary research methodologies, we ensure that our database is comprehensive, accurate, and up-to-date. The combined process involves:

Merging historical data from secondary research with real-time data from primary research.
Conducting thorough data validation and cleansing to remove inconsistencies and errors.
Organizing data into a structured format that is easily accessible and usable for various applications.
Continuously monitoring and updating the database to reflect the latest developments and trends in the healthcare field.

Through this meticulous process, we create a final database tailored to each region and domain within the healthcare industry. This approach ensures that our clients receive reliable and relevant data, empowering them to make informed decisions and drive innovation in their respective fields.